mRNA combination vaccine market seen reaching $31.57 billion by 2030

The Business Research Company says the mRNA combination vaccine market will grow from $13.18 billion in 2025 to $31.57 billion by 2030, driven by respiratory illness demand, broader immunization programs and new multi-pathogen vaccine platforms. North America led in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - mRNA combination vaccines are positioned as a way to protect against multiple pathogens or virus strains with one injection. - The market outlook points to faster adoption of simplified vaccination regimens as respiratory disease burdens rise. - The forecast suggests growing commercial interest in next-generation vaccine platforms aimed at broader and more convenient protection.

What happened: - The Business Research Company released a report on the messenger ribonucleic acid (mRNA) combination vaccine market on Sept. 10, 2026. - The report projects the market will rise from $13.18 billion in 2025 to $15.67 billion in 2026. - The report sees the market reaching $31.57 billion by 2030. - The report uses a 2025-2030 compound annual growth rate of 19.1%. - The report also cites 2026 market-report updates including market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - Download a free sample of the report. - View the full report.

The details: - The report says recent market growth has been supported by respiratory infections, government immunization programs, broader adoption of mRNA vaccine technology, pandemic preparedness efforts, and higher vaccine research and development spending. - The report says future growth will be fueled by multi-pathogen vaccine platforms, simplified vaccination regimens, personalized vaccine innovations, focus on elderly and immunocompromised groups, and wider access initiatives. - The report highlights expected trends including pan-respiratory vaccines, single-dose combination vaccines, age-specific formulations, next-generation multi-pathogen vaccines, and more investment in preventing respiratory diseases. - mRNA combination vaccines use mRNA technology to trigger the body to produce proteins that prompt an immune response. - These vaccines are designed to reduce the number of shots needed while broadening protection against multiple diseases. - The report identifies escalating respiratory illness as a primary growth driver. - Respiratory diseases cited in the report include influenza, COVID-19 and respiratory syncytial virus, or RSV. - The report says these illnesses are especially burdensome for older adults and other high-risk groups. - The US Centers for Disease Control and Prevention reported about 40 million influenza cases, 470,000 hospitalizations and 28,000 deaths in the 2023-2024 season. - Those figures were up about 29.0%, 30.6% and 33.3%, respectively, from the previous season.

Between the lines: - The market forecast reflects a broader push to combine vaccination coverage and reduce the number of clinic visits or injections. - The emphasis on elderly and immunocompromised patients suggests developers are targeting groups with the highest need for broader respiratory protection. - The report’s regional outlook shows where demand and investment may cluster next, with developed markets leading now and faster growth shifting toward emerging ones.

What's next: - North America held the largest share of the market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - Other regions covered in the analysis include South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report points to continued investment in vaccine research, multi-pathogen platforms and broader immunization access as the market expands.

The bottom line: - mRNA combination vaccines are moving from a niche innovation toward a larger respiratory-prevention market, with strong growth projected through 2030.